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ABSTRACT
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematopoietic 
malignancy characterized by dismal prognosis and overall poor therapeutic response. 
Since the biology of BPDCN is barely understood, our study aims to shed light on the 
genetic make-up of these highly malignant tumors. Using targeted high-coverage 
massive parallel sequencing, we investigated 50 common cancer genes in 33 BPDCN 
samples. We detected point mutations in NRAS (27.3% of cases), ATM (21.2%), MET, 
KRAS, IDH2, KIT (9.1% each), APC and RB1 (6.1% each), as well as in VHL, BRAF, 
MLH1, TP53 and RET (3% each). Moreover, NRAS, KRAS and ATM mutations were 
found to be mutually exclusive and we observed recurrent mutations in NRAS, IDH2, 
APC and ATM. CDKN2A deletions were detected in 27.3% of the cases followed by 
deletions of RB1 (9.1%), PTEN and TP53 (3% each). The mutual exclusive distribution 
of some mutations may point to different subgroups of BPDCN whose biological 
significance remains to be explored. Oncotarget 6405 www.impactjournals.com/oncotarget
INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm 
(BPDCN) is an orphan disease with a very aggressive 
clinical course resulting in median survival times of 
12-14 months [1,2]. The male-to-female sex ratio is 
approximately 2.0-3.5:1 and the mean age at diagnosis is 
65-70 years. There is no standardized therapeutic approach 
[3] and despite initial response to chemotherapy, patients 
show a very high relapse rate, which points to an overall 
low efficacy of current therapeutic regimens [4-8].
Initially named blastic NK/T cell lymphoma or 
agranular CD4+/CD56+ hematodermic neoplasm/tumour 
[6, 9, 10, 11], BPDCN is –according to the current WHO 
classification- classified as an acute myeloid leukemia-
related precursor neoplasm [12] that has been shown to 
derive from precursors of plasmacytoid dendritic cells 
[13, 14,15, 16]. The genetic basis of this malignancy, 
however, whose comprehension may yield new and more 
efficient therapeutic strategies, remains largely enigmatic 
[17]. As with other rare diseases, the low prevalence of 
BPDCN and its only quite recent recognition as a distinct 
tumour entity are major obstacles for comprehensive 
and systematic clinical and biological research efforts. 
Consequently, until now only few studies with limited 
numbers of cases have focused on the genetic foundations 
of BPDCN, mainly investigating copy number variations 
of tumor suppressor genes including TP53 and RB1 
[18, 19, 20, 21]. Two more recent studies [18, 22] also 
addressed somatic point mutations in the genome of 
BPDCN. To complement previous efforts and to gain more 
insight into the genetic basis of BPDCN, we performed 
targeted ultra-deep semiconductor-based massive parallel 
sequencing of 50 cancer-related genes [23] in 33 formalin-
fixed, paraffin embedded primary BPDCN samples and 
additionally assayed CDKN2A copy numbers. 
RESULTS
Thirty-three cases of BPDCN were analyzed for 
somatic mutations of 50 common cancer genes by ultra-
deep targeted semiconductor-based massive parallel 
sequencing. A detailed overview of detected SNPs 
including allele frequencies is given in supplementary 
table 1. Patient demographics are described in table 1. 
Twenty-seven patients (81.8%) were male and the median 
age was 72 years. Except for one case with manifestation 
in the nasopharynx, all biopsy specimens were obtained 
from cutaneous infiltrates. 
Sequence analysis performed with an average read 
depth of 1.552-fold identified point mutations in 14 genes 
and deletions in 4 genes. As depicted in figure 1, 4 cases 
(12.1%) showed no detectable genetic alteration in the 50 
genes investigated. For the other 29 cases (87.8%), the 
most frequent non-synonymous point mutations were 
found in NRAS (9/33 cases; 27.3%) and ATM (7/33; 
21.2%).  Point  mutations  at  lower  frequencies  were 
detected in MET, KRAS, IDH2 and KIT (3/33; 9.1% 
each), APC and RB1 (2/33; 6.1% each), and VHL, BRAF, 
MLH1, TP53 and RET (1/33; 3% each). Deletions were 
most  prevalent  in  CDKN2A  (9/33;  27.3%)  followed 
by  RB1  (3/33;  9.1%),  PTEN  and  TP53  (1/33;  3%). 
For CDKN2A deletions we performed a copy number 
assay to exemplarily validate our sequencing data by 
an independent method and corroborated all CDKN2A 
deletions detected by sequencing analysis. Figure 2 
summarizes the frequency of genetic alterations (SNP and 
CNV combined) per gene.
Mutations in either RAS genes or ATM were present 
in 57.6% of cases and in a mutually exclusive distribution 
(figure 1). Notably, 16 (48.5%) cases displayed somatic 
alterations in two or more genes.
Figure 3 depicts the type of point mutation 
and resulting amino acid substitution for all BPDCN 
Figure 1: Distribution of recurrent and mutually exclusive point mutations (green color) in known cancer genes as well as of 
deletions (red color) in CDKN2A, PTEN, TP53 and RB1 across BPDCN cases.Oncotarget 6406 www.impactjournals.com/oncotarget
specimens showing recurrent mutations in NRAS, IDH2, 
APC and ATM. Except for a nonsense mutation in RB1, 
mutations in the other genes were of missense type. 
Interestingly, as depicted in figures 1 and 3, one 
case showed concomitant deletion of one TP53 allele 
and a double mutation in the remaining TP53 allele 
and we also found two exceedingly rare mutations in 
KRAS (p.Gln22Lys and p.Leu23Arg), which have been 
documented in Cosmic but not reported in the literature 
yet.
As expected, all mutations in genes coding for the 
MAPK cascade i.e. KRAS, NRAS genes and BRAF as 
well as point mutations in the tumor suppressor genes 
APC, VHL, RB1 and TP53 were classified as deleterious/
damaging by four independent in silico tools (table 2). 
While mutations in MET and KIT as two potential drug 
targets were predicted as neutral, we found deleterious 
missense  mutations  in ATM  and  RET,  both  encoding 
proteins of the DNA damage response. 
DISCUSSION
Here, we performed targeted high-coverage massive 
parallel sequencing of 50 common cancer genes in 33 
cases of BPDCN. We found recurrent mutations in 4 
cancer genes and delineated that NRAS, KRAS and ATM 
mutations are distributed in a mutually exclusive fashion.
BPDCN is a rare and aggressive hematologic 
malignancy, whose pathobiology is still largely obscure. 
Over the last 5 years studies on the genetic foundations 
Figure 2: Frequency of genetic alterations (SNP and 
CNV) of known cancer genes in BPDCN (bar plot) in 
percent (descending order). COUNT indicates absolute 
numbers of cases.
Table 1: Basic clinical characteristics of BPDCN cases. 
ID No. Age [y] Sex Origin of tissue
01 77 f skin
02 85 m skin
03 81 m skin
04 83 m skin
05 60 m skin
06 69 m skin
07 73 m skin
08 79 m skin
09 67 m skin
10 81 m skin
11 76 m skin
12 69 m skin
13 30 m skin
14 69 m skin
15 83 m skin
16 71 f skin
17 82 m skin
18 76 m skin
19 54 f skin
20 64 f skin
21 83 m skin
22 89 m skin
23 68 f nasopharynx
24 87 m skin
25 60 m skin
26 76 m skin
27 72 m skin
28 65 m skin
29 60 m skin
30 80 m skin
31 52 f skin
32 61 m skin
33 72 m skin
f: female, m: male; Age: age at diagnosis, y: yearsOncotarget 6407 www.impactjournals.com/oncotarget
Table 2: In silico characterization of gene mutations including COSMIC annotations
Gene/Mutation Mutation
Taster
PolyPhen SIFT PROVEAN COSMIC
NRAS: p.Gly12Asp
Disease 
causing
possibly 
damaging Damaging Deleterious
COSM564  (n=450;  324  samples  in  haematopoietic  and 
lymphoid tissue: i. a. leukemia,  myelodysplastic syndrome), 
COSM46495 (n=4, leukemia)
NRAS: p.Gly12Ala
Disease 
causing
possibly 
damaging
Damaging Deleterious
COSM565 (n=52; 36 samples in haematopoietic and lymphoid 
tissue: i. a. leukemia, BPDCN)
NRAS: p.Gly12Val Disease 
causing
possibly 
damaging
Damaging Deleterious COSM566 (n=72; 55 samples in haematopoietic and lymphoid 
tissue: i. a. leukemia, myeloproliferative disease)
NRAS: p.Gly13Val
Disease 
causing
probably 
damaging Damaging Deleterious
COSM574  (n=61;  40  samples  in  haematopoietic  and 
lymphoid tissue: i.a. leukemia, myelodysplastic syndromes, 
myeloproliferative  disease,  lymphoma)  COSM46502  (n=1, 
leukemia)
NRAS: p.Ala146Val Disease 
causing
probably 
damaging Damaging Deleterious No COSMIC entry
KRAS: p.Gln22Lys Disease 
causing
probably 
damaging
Damaging Deleterious COSM543 (n=9; 1 sample in haematopoietic and lymphoid 
tissue: leukemia)
KRAS: p.Leu23Arg
Disease 
causing
probably 
damaging
Damaging Deleterious
COSM303853 (n=1; 1 sample in haematopoietic and lymphoid 
tissue: leukemia)
KRAS: p.Lys117Asn Disease 
causing
probably 
damaging
Damaging Deleterious COSM28519 (n=6; 2 samples in haematopoietic and lymphoid 
tissue: leukemia)
ATM: p.Phe858Leu Polymorphism possibly 
damaging
Tolerated Deleterious COSM21826 (3 samples in haematopoietic and lymphoid tissue: 
Lymphoma)
ATM: p.Pro1296Ser Polymorphism
probably 
damaging Damaging Deleterious no COSMIC entry
ATM: p.Ile2888Thr   Disease 
causing
probably 
damaging
Damaging Deleterious COSM21679 (2 samples in haematopoietic and lymphoid tissue: 
leukemia, lymphoma)
IDH2: p.Arg140Gln Disease 
causing
probably 
damaging
Damaging Deleterious
COSM41590  (n=379;  378  samples  in  haematopoietic  and 
lymphoid tissue: i. a. BPDCN, myeloproliferative disease, 
myelodysplastic syndrome, Leukemia)
KIT: p.Met541Leu Polymorphism benign Tolerated Neutral COSM28026  (n=31;  16  samples  in  haematopoietic  and 
lymphoid tissue: pediatric Mastocytosis, myeloid malignancies)
APC: p.Ala1582Pro Disease 
causing
probably 
damaging
Damaging Deleterious no COSMIC entry
MET: p.Glu168Asp Polymorphism possibly 
damaging
Tolerated Neutral
COSM706  (n=2),  COSM29811  (n=4;  1  sample  in 
haematopoietic  and  lymphoid  tissue:  Langerhans  cell 
histiocytosis)
MET: p.Asn375Ser
Disease 
causing benign Tolerated Neutral COSM710 (n=3), COSM28925 (n=18)
RB1: p.Asp332Gly Disease 
causing
probably 
damaging
Damaging Deleterious no COSMIC entry
RB1: p.Arg358* 
Disease 
causing
Nonsense Nonsense Nonsense COSM879 (n=6)
TP53: p.His179Arg
Disease 
causing
probably 
damaging
Damaging Deleterious COSM10889 (n=114), COSM87198 (n=5)
TP53: p.Asp281Tyr
Disease 
causing
probably 
damaging Damaging Deleterious
COSM11516 (n=10; 1 sample in haematopoietic and lymphoid 
tissue: lymphoma)
VHL: p.Pro81Ser Disease 
causing
possibly 
damaging
Damaging Deleterious COSM17721 (n=16) COSM144163 (n=1)
BRAF: p.Gly469Ala
Disease 
causing
probably 
damaging
Damaging Deleterious
COSM460 (n=31; 6 samples in haematopoietic and lymphoid 
tissue: leukemia, lymphoma), COSM29608 (n=21)
MLH1:p.Arg385Cys Disease 
causing
probably 
damaging
Damaging Deleterious COSM1422593 (n=1)
RET:p.Ser649Leu
Disease 
causing
probably 
damaging Damaging Neutral no COSMIC entryOncotarget 6408 www.impactjournals.com/oncotarget
of BPDCN revealed a peculiar genotype with a complex 
karyotype  and  recurrent  deletions  in  several  tumor 
suppressor genes, such as RB1, TP53, CDKN2A and 
CDKN2B [19, 20, 21, 28]. While the data on copy number 
variations seem to be rather specific for BPDCN among 
hematologic neoplasms, recent work [18, 29] demonstrated 
point mutations in TET2 und TP53 in the genome of 
BPDCN thereby genetically relating BPDCN to a broad 
range of myeloid malignancies, where recurrent mutations 
particularly in the tumour suppressor TET2 but also in 
TP53 are highly prevalent [30, 31]. In accord with these 
reports, we detected deletions, which were most prevalent 
for CDKN2A and less frequent for RB1, TP53 and PTEN. 
Moreover  we  found  point  mutations  in  TP53,  IDH2, 
KRAS and NRAS further underpinning a genetic relation 
between BPDCN and myeloid malignancies, including 
acute myeloid leukemia and myelodysplastic syndrome. 
Thereby, our findings extend the observations of prior 
studies and support the genetic rationale for the current 
WHO classification of BPDCN as a distinct precursor 
neoplasm that relates to acute myeloid leukemia. In this 
context it is notable that we did not find mutations in other 
genes that have been described in myeloid malignancies, 
such as FLT3, NPM1, IDH1, JAK2, and EZH2. A very 
recent study by Menezes et al [22], who used a combined 
approach of whole exome sequencing-based identification 
of major genetic aberrations and targeted resequencing of 
25 BPDCN, found similar frequencies of mutations in 
NRAS and corroborated TET2 mutations albeit at a lower 
frequency as reported previously [18, 29]. Additionally, 
they identified mutations in genes not included in our 
gene panel, namely in ASXL1 and in the transcription 
factors IKZF1-3 and ZEB2. Taken together, these findings 
strongly support the view that BPDCN is a distinct entity 
within the spectrum of myeloid malignancies.
Interestingly, we discovered missense mutations in 
DNA damage response genes, i.e. MLH1 and ATM in a 
substantial number of cases. Of three ATM variants, we 
have detected in our cohort, two are already reported in the 
Cosmic database and all three are classified as damaging 
by the majority of the in silico prediction models used 
herein. ATM aberrations have been mainly implicated 
Figure 3: Distribution of non-synonymous somatic mutation types in known cancer genes across BPDCN samples. Amino 
acid substitutions as indicated.Oncotarget 6409 www.impactjournals.com/oncotarget
in the development of lymphomas, including T-cell 
prolymphocytic leukemia [32], mantle cell lymphoma 
[33], diffuse large B-cell lymphoma [34] and B-cell 
chronic lymphocytic leukemia [35]. Although we do not 
know yet what these ATM mutations actually mean for 
BPDCN biology, In the light of the above mentioned 
studies, our genetic data may point to a shared trait with 
lymphoid  malignancies.  In  line  with  these  findings, 
BPDCN express also molecules that can be found in 
malignant lymphomas, such as CD4 and CD123 and it 
has been demonstrated in mice that normal plasmacytoid 
dendritic cells retain remarkable differentiation plasticity 
and can derive from both myeloid and lymphoid 
progenitors [36]. Also, a recent study conducted 
by Sapienza et al [37] found BPDCN to display an 
ambiguous expression profile that indeed related to both 
acute lymphoid and acute myeloid leukemia. Moreover, 
although these data do not stem from randomized clinical 
trials and therefore have to be interpreted carefully, several 
clinical reports have demonstrated a considerable efficacy 
of acute lymphoid leukemia-like protocols in BPDCN 
treatment [38, 39]. 
While it is well known that RAS signaling plays 
a role in other hematologic malignancies, our study 
shows for the first time that BPDCN specimens have 
mutually exclusive mutations in NRAS and KRAS and 
recurrent mutations in NRAS. Our study suggests that 
the prevalence of RAS mutations in approximately 
35%  of  BPDCN  even  exceeds  the  ones  reported  for 
other hematological neoplasms known to harbor RAS-
mutations,  namely  juvenile  myelomonocytic  leukemia 
(JMML), chronic myelomonocytic leukemia (CMML), 
acute  myeloid  leukemia  (AML),  myelodysplastic 
syndrome (MDS), acute lymphoblastic leukemia (ALL) 
and multiple myeloma (MM) [40]. As already reported 
for these neoplasms, BPDCN also shows a clear 
predominance of NRAS mutations over KRAS mutations. 
Although tremendous research efforts are being made, 
powerful and clinically effective inhibition of mutated 
RAS is still at a distant prospect. However, given the 
high prevalence of mutated RAS genes, targeting Ras 
or downstream effectors of the MAPK-pathway such as 
MEK and ERK [41, 42] would be a valuable treatment 
option for BPDCN.
Since mutations in NRAS and KRAS as well as in 
ATM were found to be recurrent and mutually exclusive, 
it is tempting to speculate whether these data point 
to genetically distinct subgroups within the BPDCN 
phenotype. 
At this point the lack of reliable BPDCN models 
precludes functional analysis or the study of biological 
implications of our genetic data. Furthermore, the overall 
rarity of BPDCN precludes analysis of clinical course or 
outcome data. Nonetheless, our sample size of 33 primary 
tumour samples at least equals or exceeds the number of 
specimens in prior studies [18, 22]. In conjunction with 
these studies, here, we extend the genetic framework of 
BPDCN, which is an important step in understanding the 
pathobiology of BPDCN and may also aid in finding novel 
therapeutic options for this orphan disease.
MATERIAL AND METHODS
Ethics statement
This study was conducted as an anonymized case- 
and specimen review via the tissue bank of the National 
Center for Tumor Diseases (NCT, Heidelberg, Germany). 
All experiments were performed in accordance with the 
Declaration of Helsinki.
Samples
Formalin-fixed,  paraffin  embedded  tissue  from 
33 cases of BPDCN were obtained from the Institute of 
Pathology and Department of Dermatology, University 
Hospital Heidelberg, the Institute of Pathology, 
Charité University Hospital, Berlin, the Institute of 
Pathology at the University of Leipzig, the Department 
of Pathology, Christian-Albrechts-University of Kiel, 
and the Department of Dermatology, Venereology and 
Allergology,  University  Medical  Center  and  Medical 
Faculty Mannheim, University of Heidelberg. All cases 
were diagnosed by experienced haematopathologists (AM, 
IA, KJ, WK, CW) according to the criteria of the World 
Health Organization classification of heamatopoietic and 
lymphoid tissue [12]. Patient data were anonymized. Due 
to the fact that the majority of cases had been sent for 
consultation no follow-up data were available.
DNA extraction
Extraction of genomic DNA was performed by 
proteinase K digestion and fully automated purification 
using the QIASymphonySP (Qiagen, Hilden, Germany). 
The total DNA content was measured using the QuBit HS 
DNA Assay (Life Technologies, Darmstadt, Germany), 
followed by measuring the amount of amplifiable DNA 
using quantitative PCR [23].
Library preparation and semiconductor 
sequencing
For this study the multiplex PCR based Ion 
Torrent AmpliSeq cancer Hotspot panel version 2 
(Life  Technologies,  Darmstadt,  Germany)  was  used, 
covering approx. 2,800 COSMIC annotated mutations 
in  the  following  50  key  cancer  genes: ABL1, AKT1, Oncotarget 6410 www.impactjournals.com/oncotarget
ALK, APC, ATM,  BRAF,  CDH1,  CDKN2A,  CSF1R, 
CTNNB1,  EGFR,  ERBB2,  ERBB4,  EZH2,  FBXW7, 
FGFR1,  FGFR2,  FGFR3,  FLT3,  GNA11,  GNAS, 
GNAQ,  HNF1A,  HRAS,  IDH1,  IDH2,  JAK2,  JAK3, 
KDR,  KIT,  KRAS,  MET,  MLH1,  MPL,  NOTCH1, 
NPM1,  NRAS,  PDGFRA,  PIK3CA,  PTEN,  PTPN11, 
RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, 
TP53,  and  VHL.  Amplicon  library  preparation  was 
performed using approximately 10 ng of DNA as 
advised  by  the  manufacturer.  Briefly,  the  DNA  was 
mixed with the primer pool, containing all primers for 
generating the 207 amplicons, and the AmpliSeq HiFi 
Master Mix and transferred to a PCR cycler (Biometra, 
Göttingen,Germany). PCR cycling conditions were as 
follows: Initial denaturation: 99°C for 2 min, cycling: 21 
cycles of 99°C, 15 sec and 60°C, 4 min. After the end 
of the PCR reaction, primer end sequences were partially 
digested using FuPa reagent as instructed, followed 
by the ligation of barcoded sequencing adapters (Ion 
Xpress Barcode Adapters, Life Technologies, Darmstadt, 
Germany). The final library was purified using AMPure 
XP magnetic beads (Beckman Coulter, Krefeld, Germany) 
and  quantified  using  qPCR  (Ion  Library  Quantitation 
Kit,  Life  Technologies,  Darmstadt,  Germany)  on  a 
StepOne Plus Instrument (Life Technologies, Darmstadt, 
Germany). The individual libraries were diluted to a final 
concentration of 100pM and eight to ten libraries were 
pooled  and  processed  to  library  amplification  on  Ion 
Spheres using the Ion OneTouch 2 instrumentation with 
the 200 bp chemistry. Unenriched libraries were quality-
controlled using Ion Sphere quality control measurement 
on a QuBit instrument. After library enrichment (Ion 
OneTouch ES), the library was processed for sequencing 
using the Ion Torrent 200 bp sequencing chemistry and the 
barcoded eight to ten libraries were loaded onto a single 
318 chip. 
Data analysis
Raw data analysis was performed using Ion Torrent 
Software Suite (Version 3.6 and 4.0, respectively). The 
reads were aligned to the human reference sequence 
build 38 (hg19) using the TMAP aligner implemented 
in the Torrent Suite software. Detection of single base 
pair variants and insertion-deletion polymorphisms 
(InDels) compared to the human reference sequence was 
performed using either Ion Torrent Variant Caller (3.6 
and 4.0). Detection thresholds for SNPs and InDels were 
set at an allele frequency of 5%. Variants were annotated 
and filtered against the dbSNP and COSMIC databases 
and screened for possible splice site effect using the CLC 
genomics  Suite  6  (CLCbio, Aarhus,  Denmark).  Copy 
number variation was determined using the coverage 
analysis plug-in of the Torrent Suite software.
Copy number alterations
All tissue samples were analyzed for CDKN2A 
copy number using a Taqman® copy number assay (Life 
Technologies, Carlsbad, CA) to measure copy number 
variation at the CDKN2A locus. The assay is a duplex 
polymerase chain reaction (PCR) for the CDKN2A 
gene and the reference gene, RNaseP (normalizer), 
using 10 ng DNA in quadruplicate PCR according to the 
manufacturer’s protocol and run on the StepOnePlus real 
time PCR instrument (Life Technologies). The results 
were calculated as a ratio relative to a 2-copy control 
using the Copy Caller software (Life Technologies). Loss 
of CDKN2A was defined as ≤1.5 copies, no loss was >1.5 
copies.
In silico analysis of mutations
The biological impact of the mutations on the 
structure and function of the respective protein product 
was predicted in silico by the use of four different software 
tools: Provean (http://provean.jcvi.org/index.php) [24], 
Sift  (http://sift.jcvi.org/)  [25],  MutationTaster  (http://
www.mutationtaster.org/) [26] and PolyPhen (http://
genetics.bwh.harvard.edu/pph/data/) [27]. Additionally 
we used the COSMIC (catalogue of somatic mutations in 
cancer) database to check our sequencing data for somatic 
mutations that have already been reported elsewhere.
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